Pharmacokinetics of Remdesivir and GS-441524 during PIRRT and Seraph 100 Therapy

Clin J Am Soc Nephrol. 2021 Aug;16(8):1256-1257. doi: 10.2215/CJN.17601120. Epub 2021 Jul 23.

Authors

Julius J Schmidt¹, Stefanie M Bode-Böger², Jens Martens-Lobenhoffer², Marius M Hoeper³, Jan T Kielstein⁴

Affiliations

¹ Department of Nephrology and Hypertension, Hannover Medical School, Hannover, Germany.
² Institute of Clinical Pharmacology, Otto von-Guericke-University of Magdeburg, Magdeburg, Germany.
³ Department of Pulmonary Medicine, Hannover Medical School, Hannover, and German Centre of Lung Research, Hannover, Germany.
⁴ Nephrology, Rheumatology, and Blood Purification, Medical Clinic V, Academic Teaching Hospital Braunschweig, Braunschweig, Germany.

No abstract available

Keywords: COVID-19; PIRRT; remdesivir.

MeSH terms

Adenosine / analogs & derivatives*
Adenosine / pharmacokinetics
Adenosine Monophosphate / analogs & derivatives*
Adenosine Monophosphate / pharmacokinetics
Adult
Aged
Alanine / analogs & derivatives*
Alanine / pharmacokinetics
COVID-19 Drug Treatment*
Female
Hemofiltration*
Humans
Intermittent Renal Replacement Therapy*
Male
SARS-CoV-2*

Substances

GS-441524
remdesivir
Adenosine Monophosphate
Adenosine
Alanine